A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Ruxolitinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 02 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 21 Jan 2017 Results of dose finding phase (n=42), presented at the 2017 Gastrointestinal Cancers Symposium.
- 02 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.